Ipsen Toekomstige groei
Future criteriumcontroles 1/6
Ipsen zal naar verwachting groeien in winst en omzet met respectievelijk 11.6% en 4.2% per jaar. De winst per aandeel zal naar verwachting groeien met 13.2% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 16.2% zijn.
Belangrijke informatie
11.6%
Groei van de winst
13.20%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 16.0% |
| Inkomstengroei | 4.2% |
| Toekomstig rendement op eigen vermogen | 16.17% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 18 May 2026 |
Recente toekomstige groei-updates
Recent updates
Narratiefupdate • May 17
IPN: Future Portfolio Execution And Core Pipeline Will Shape Re Rated Earnings Potential
Analysts have raised Ipsen's price target by €13 to €183, citing updated assumptions around the discount rate, revenue growth, profit margins and future P/E that align with recent upward revisions from major banks. Analyst Commentary Recent research updates point to a more constructive stance on Ipsen, with several bullish analysts revisiting their models and price targets.Narratiefupdate • Apr 24
IPN: Future Portfolio Execution Will Drive Re Rated Earnings Power Potential
Narrative Update on Ipsen The analyst fair value estimate for Ipsen has been revised from €155 to €183. This reflects analysts' updated assumptions on higher revenue growth, a different discount rate, a higher future P/E and recent price target increases and rating changes across several banks.
Narratiefupdate • Apr 10
IPN: Oncology Pipeline Progress And Safety Setbacks Will Shape Balanced Future Outlook
Analysts have adjusted the Ipsen price target to €151.94, with recent research pointing to updated revenue growth and profit margin assumptions, as well as fresh Street targets around €160 and €170 as key drivers of the new view. Analyst Commentary Bullish Takeaways Bullish analysts are pointing to higher price targets around €160 and €170, which reflects confidence in Ipsen’s ability to execute on its current pipeline and financial framework despite recent product-specific issues.Narratiefupdate • Mar 27
IPN: Early Oncology Pipeline And Safety Setbacks Will Shape Future Upside
The analyst fair value estimate for Ipsen has shifted from €143 to about €152, as analysts factor in updated price targets around €160 to €170 and recent rating changes that reflect both the impact of the tazemetostat withdrawal and a focus on the broader pipeline and earnings profile. Analyst Commentary Recent research shows a split view on Ipsen, with some bullish analysts lifting price targets toward €160 to €170, while more cautious voices highlight pipeline depth and valuation risks after the tazemetostat withdrawal.
Narratiefupdate • Mar 13
IPN: Oncology Setbacks And Limited Late Stage Pipeline Will Constrain Future Upside
The analyst fair value estimate for Ipsen has shifted from €105 to €115, with analysts pointing to recent price target revisions, mixed views on the company’s pipeline depth, and updated assumptions on margins and future P/E levels as key drivers of the change. Analyst Commentary Recent Street research around Ipsen has focused on shifting views of the company’s pipeline and valuation, with mixed reactions to the withdrawal of tazemetostat and differing opinions on the depth of late stage assets.Narratiefupdate • Feb 27
IPN: Limited Late Stage Pipeline Will Constrain Future Upside Potential
The analyst fair value estimate for Ipsen has moved from €134.80 to €143.00, reflecting updated assumptions on revenue growth, margins, and future P/E, following recent price target changes from banks that now range from about €125 to €170. Analyst Commentary Recent research on Ipsen reflects a mix of optimism and caution, with target prices clustering between about €125 and €170 and ratings spread across Buy, Neutral, and Equal Weight.Narratiefupdate • Feb 12
IPN: Competitive Pressures And Thin Pipeline Will Shape A Balanced Outlook
Analysts have increased their fair value estimate for Ipsen to about €135 per share from roughly €133, reflecting updated price targets that incorporate a mix of cautious views on the late stage pipeline and concerns around competitive pressures, alongside modest target increases from others. Analyst Commentary Recent research shows a split view on Ipsen, with some analysts trimming expectations and others nudging targets higher.Narratiefupdate • Jan 29
IPN: Mixed Ratings And Limited Late Stage Assets Will Shape A Balanced Outlook
Narrative Update The updated analyst price target for Ipsen moves modestly higher to about €133 from about €131. Analysts point to slightly stronger revenue growth and margin assumptions, while also flagging ongoing concerns about limited late stage assets and competitive pressure on Somatuline, as reflected in recent mixed rating and target changes from UBS, Barclays, and BNP Paribas Exane.Narratiefupdate • Jan 15
IPN: Mixed Ratings And Pipeline Setbacks Will Shape A Cautious Yet Balanced Outlook
Our updated fair value estimate for Ipsen edges up from €130.07 to €130.79. This reflects a blend of mixed Street signals, where some analysts point to valuation constraints and pipeline depth, while others lift price targets in line with current expectations.Narratiefupdate • Dec 21
IPN: Guidance Upgrade And Competitive Pressures Will Shape A Cautious Yet Balanced Outlook
Analysts have reduced their price target on Ipsen from EUR 130.07 to EUR 105.00, citing increased competitive pressure on Somatuline as a key driver of the downgrade. Analyst Commentary Analysts note that the reduced price target reflects a reassessment of Ipsen's risk and reward profile in light of mounting competition for Somatuline, which is expected to weigh on both top line momentum and margin resilience.Narratiefupdate • Dec 07
IPN: Guidance Upgrade And Competition Concerns Will Shape Balanced Future Outlook
Analysts have trimmed their price target on Ipsen by approximately EUR 1 to around EUR 130, reflecting slightly lower long term growth and margin expectations amid rising competitive pressure on key drug Somatuline. Analyst Commentary Analyst sentiment around Ipsen has turned more cautious, with recent revisions reflecting heightened concern about the sustainability of growth in key endocrine oncology franchises and the implications for valuation.Narratiefupdate • Nov 22
IPN: Guidance Upgrade And New Approvals Will Support Balanced Outlook
Narrative Update on Ipsen Analysts have maintained their fair value estimate for Ipsen at €130.79 per share. They cite minimal changes in key assumptions and only slight fluctuations in projected growth and profitability.Narratiefupdate • Nov 07
IPN: Future Opportunities And Risks Are Balanced Following Guidance Upgrade
Narrative Update on Ipsen: Analyst Price Target Adjustment Analysts have raised their price target for Ipsen to €130.79, up from €129.93. This change reflects slight improvements in expected revenue growth and profit margin, despite a marginally higher discount rate.Analyseartikel • Oct 28
Ipsen (EPA:IPN) Seems To Use Debt Rather Sparingly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Narratiefupdate • Oct 24
Global Approvals And Guidance Will Drive Expanded Patient Access Worldwide
Narrative Update on Ipsen: Analyst Price Target Adjustment Analysts have slightly increased their price target for Ipsen from $128.43 to $129.93. This adjustment is attributed to minor shifts in revenue growth forecasts and updated profit margin estimates.Narratiefupdate • Sep 25
Pipeline Catalysts And Approvals Will Expand Global Access
Driven by a modest uptick in consensus revenue growth forecasts and a slight increase in the projected future P/E, Ipsen’s analyst price target has inched up from €127.00 to €128.43. What's in the News Ipsen received Japanese regulatory approval for Bylvay (odevixibat) for the treatment of pruritus associated with progressive familial intrahepatic cholestasis (PFIC), with commercialization managed by Ipsen in Japan.Analyseartikel • Sep 07
Are Investors Undervaluing Ipsen S.A. (EPA:IPN) By 41%?
Key Insights Ipsen's estimated fair value is €205 based on 2 Stage Free Cash Flow to Equity Current share price of €120...Analyseartikel • Jul 13
Investors Interested In Ipsen S.A.'s (EPA:IPN) Earnings
Ipsen S.A.'s ( EPA:IPN ) price-to-earnings (or "P/E") ratio of 24.5x might make it look like a strong sell right now...
Nieuw narratief • Feb 23
Cabometyx And Tovorafenib Approvals May Strengthen Oncology Portfolio In 2025
Expansion of Onivyde and new product approvals could significantly increase revenue and strengthen market positions in key medical segments.Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2028 | 4,669 | 932 | 1,092 | 1,209 | 8 |
| 12/31/2027 | 4,387 | 886 | 1,044 | 1,117 | 12 |
| 12/31/2026 | 4,238 | 895 | 1,026 | 1,371 | 11 |
| 12/31/2025 | 3,929 | 444 | 810 | 1,138 | N/A |
| 9/30/2025 | 3,845 | 446 | 703 | 1,057 | N/A |
| 6/30/2025 | 3,760 | 448 | 595 | 976 | N/A |
| 3/31/2025 | 3,667 | 402 | 364 | 946 | N/A |
| 12/31/2024 | 3,575 | 356 | 133 | 916 | N/A |
| 6/30/2024 | 3,435 | 664 | 212 | 903 | N/A |
| 3/31/2024 | 3,371 | 641 | 445 | 884 | N/A |
| 12/31/2023 | 3,306 | 617 | 677 | 866 | N/A |
| 6/30/2023 | 3,282 | 406 | 764 | 972 | N/A |
| 3/31/2023 | 3,219 | 500 | 741 | 971 | N/A |
| 12/31/2022 | 3,156 | 593 | 719 | 971 | N/A |
| 9/30/2022 | 3,053 | 656 | 615 | 972 | N/A |
| 6/30/2022 | 2,950 | 719 | 512 | 973 | N/A |
| 3/31/2022 | 2,849 | 675 | 494 | 933 | N/A |
| 12/31/2021 | 2,749 | 631 | 475 | 893 | N/A |
| 9/30/2021 | 2,712 | 626 | 570 | 860 | N/A |
| 6/30/2021 | 2,676 | 622 | 665 | 827 | N/A |
| 3/31/2021 | 2,681 | 585 | 649 | 799 | N/A |
| 12/31/2020 | 2,686 | 548 | 632 | 771 | N/A |
| 9/30/2020 | 2,697 | 249 | 564 | 750 | N/A |
| 6/30/2020 | 2,707 | -50 | 496 | 729 | N/A |
| 3/31/2020 | 2,700 | -53 | 421 | 678 | N/A |
| 12/31/2019 | 2,693 | -55 | 347 | 628 | N/A |
| 9/30/2019 | 2,605 | 176 | N/A | 591 | N/A |
| 6/30/2019 | 2,516 | 406 | N/A | 555 | N/A |
| 3/31/2019 | 2,432 | 397 | N/A | 563 | N/A |
| 12/31/2018 | 2,348 | 388 | N/A | 571 | N/A |
| 9/30/2018 | 2,258 | 365 | N/A | N/A | N/A |
| 6/30/2018 | 2,167 | 343 | N/A | 502 | N/A |
| 3/31/2018 | 2,090 | 307 | N/A | 463 | N/A |
| 12/31/2017 | 2,012 | 270 | N/A | 423 | N/A |
| 9/30/2017 | 1,923 | 243 | N/A | N/A | N/A |
| 6/30/2017 | 1,834 | 217 | N/A | 316 | N/A |
| 3/31/2017 | 1,753 | 221 | N/A | 317 | N/A |
| 12/31/2016 | 1,671 | 226 | N/A | 318 | N/A |
| 9/30/2016 | 1,623 | 229 | N/A | N/A | N/A |
| 6/30/2016 | 1,575 | 233 | N/A | 318 | N/A |
| 3/31/2016 | 1,548 | 211 | N/A | 271 | N/A |
| 12/31/2015 | 1,520 | 189 | N/A | 224 | N/A |
| 9/30/2015 | 1,468 | 165 | N/A | 225 | N/A |
| 6/30/2015 | 1,416 | 140 | N/A | 227 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei IPN ( 11.6% per jaar) ligt boven de spaarquote ( 2.5% ).
Winst versus markt: De winst van IPN ( 11.6% per jaar) zal naar verwachting langzamer groeien dan de markt French ( 12.4% per jaar).
Hoge groeiwinsten: De winst van IPN zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van IPN ( 4.2% per jaar) zal naar verwachting langzamer groeien dan de markt French ( 5.6% per jaar).
Hoge groei-inkomsten: De omzet van IPN ( 4.2% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen IPN zal naar verwachting over 3 jaar laag zijn ( 16.2 %).
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/21 10:36 |
| Aandelenkoers aan het einde van de dag | 2026/05/21 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Ipsen S.A. wordt gevolgd door 25 analisten. 12 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Charles Pitman | Barclays |
| Yihan Li | Barclays |
| Charles Pitman | Barclays |